SEC Form 4 · accession 0001209191-15-029916
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joshua S Boger
Director
Period of report
Mar 25, 2015
Accepted (ET)
Mar 27, 2015 · 4:48 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 25, 2015 | M | 1,300 | $17.16 | A | 387,584 | D | |
| Common Stock | Mar 25, 2015 | M | 10,400 | $35.64 | A | 397,984 | D | |
| Common StockF2,F3 | Mar 25, 2015 | S | 2,100 | $119.03 | D | 395,884 | D | |
| Common StockF3,F4 | Mar 25, 2015 | S | 3,900 | $119.88 | D | 391,984 | D | |
| Common StockF3,F5 | Mar 25, 2015 | S | 2,600 | $120.91 | D | 389,384 | D | |
| Common StockF3,F6 | Mar 25, 2015 | S | 1,900 | $122.68 | D | 387,484 | D | |
| Common StockF3,F7 | Mar 25, 2015 | S | 1,200 | $123.27 | D | 386,284 | D | |
| Common Stock | holding | — | — | — | 13,286 | I | 401(k) | |
| Common StockF8 | holding | — | — | — | 122,700 | I | Common Stock held in trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F9 | $17.16 | Mar 25, 2015 | M | 1,300 | D | — | Jul 19, 2015 | Common Stock | 1,300 | 21,300 | D |
| Stock Option (right to buy)F9 | $35.64 | Mar 25, 2015 | M | 10,400 | D | — | Feb 1, 2016 | Common Stock | 10,400 | 458,400 | D |
Explanation of responses
- F1Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.
- F2Open market sales reported on this line occurred at a weighted average price of $119.03 (range $118.50 to $119.49).
- F3Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F4Open market sales reported on this line occurred at a weighted average price of $119.88 (range $119.53 to $120.50).
- F5Open market sales reported on this line occurred at a weighted average price of $120.91 (range $120.53 to $121.43).
- F6Open market sales reported on this line occurred at a weighted average price of $122.68 (range $122.08 to $123.07).
- F7Open market sales reported on this line occurred at a weighted average price of $123.27 (range $123.10 to $123.59).
- F8Common stock held in grantor retained annuity trusts.
- F9Fully vested.